为了确定预测聚（ADP核糖）聚合酶（PARP）抑制剂对日本卵巢癌患者疗效的有用生物标志物。我们收集了 42 名卵巢癌、输卵管和原发性腹膜癌患者的临床信息并进行了分子生物学分析。在接受 PARP 抑制剂治疗的卵巢癌患者中，23.8% 的患者存在种系 BRCA 突变 (gBRCAm)，42.9% 的患者存在同源重组修复相关基因突变 (HRRm)，61.1% 的基因组不稳定性评分 (GIS) 为≥42。存在 HRRm 的患者的无进展生存期 (PFS) 明显长于不存在 HRRm 的患者（中位 PFS 35.6 个月与 7.9 个月；p=0.009），其中 gBRCAm 患者的 PFS 显着增加（中位 PFS 42.3 个月）。同样，在复发性卵巢癌患者中，具有 HRRm 的患者比不具有 HRRm 的患者具有更长的 PFS（中位 PFS 42.3 个月与 7.7 个月；p=0.040）。多变量 Cox 比例风险回归分析发现，体能状态和 gBRCAm 状态是与 PARP 抑制剂延长 PFS 相关的独立因素。在复发性卵巢癌中，多变量回归分析发现，除体能状态外，无铂间隔 (PFI) 也是 PFS 的重要预测因素。相反，临床实践中使用的 PFS 与 GIS ≥42 之间没有观察到显着关联。我们发现 HRRm 可以作为预测 PARP 抑制剂治疗卵巢癌效果的有用生物标志物，并且 PFI 也可以有用复发性卵巢癌。© 2024。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

To determine the useful biomarker for predicting the effects of poly-(ADP ribose)-polymerase (PARP) inhibitors in Japanese patients with ovarian cancer.We collected clinical information and performed molecular biological analysis on 42 patients with ovarian, fallopian tube, and primary peritoneal carcinomas who received PARP inhibitors.Among the analyzed patients with ovarian cancer, 23.8% had germline BRCA mutation (gBRCAm), 42.9% had homologous recombination repair-related gene mutation (HRRm), and 61.1% had a genomic instability score (GIS) of ≥42. Patients with HRRm had a significantly longer progression-free survival (PFS) than those without HRRm (median PFS 35.6 vs. 7.9 months; p=0.009), with a particularly marked increase in PFS in patients with gBRCAm (median PFS 42.3 months). Similarly, among patients with recurrent ovarian cancer, those with HRRm had a longer PFS than those without HRRm (median PFS 42.3 vs. 7.7 months; p=0.040). Multivariate Cox proportional hazards regression analysis found that performance status and gBRCAm status were independent factors associated with prolonged PFS with PARP inhibitors. In recurrent ovarian cancer, multivariate regression analysis identified platinum-free interval (PFI) in addition to performance status as a significant predictor of PFS. On the contrary, no significant association was observed between PFS and a GIS of ≥42 used in clinical practice.We found that HRRm can be a useful biomarker for predicting the effects of PARP inhibitors in treating ovarian cancer and that the PFI can also be useful in recurrent ovarian cancer.© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.